Makary Got His Man in Pazdur—But Can He Last as CDER Director?

Rick Pazdur has been named director of the FDA’s Center for Drug Evaluation and Research and is widely viewed by former officials and analysts as the “ideal” stabilizer for an agency that has seen multiple CDER leadership changes in the past 11 months; a 26‑year FDA veteran who founded the Oncology Center of Excellence, Pazdur is credited with accelerating oncology approvals while pulling therapies that failed confirmatory trials. Reports say he accepted the role only after Commissioner Marty Makary assured him of autonomy from CBER director Vinay Prasad—whose combative tenure has already rattled biotech stocks—and insiders warn any attempt by Prasad to supersede Pazdur could trigger resignations and internal conflict. For investors, Pazdur’s appointment likely improves near‑term regulatory predictability and signals continued support for accelerated/conditional approval pathways (especially in oncology and rare diseases), but execution risk from ongoing agency power struggles remains.

Analysis

Rick Pazdur has been named director of the FDA’s Center for Drug Evaluation and Research (CDER) after a week in the role and is a 26-year FDA veteran who founded the Oncology Center of Excellence in 2017; his appointment follows rapid CDER leadership turnover—Patrizia Cavazzoni to Jacqueline Corrigan-Curay (acting) to George Tidmarsh to Pazdur within 11 months—and reports say he only accepted after Commissioner Marty Makary assured him autonomy from CBER director Vinay Prasad. Market and regulatory commentators including RBC’s Brian Abrahams and Friends of Cancer Research chair Ellen Sigal describe Pazdur as a stabilizing, well‑respected leader who has historically sped oncology approvals while withdrawing therapies that failed confirmatory trials, signaling likely continuity for accelerated/conditional approval pathways that Makary is promoting. Tension risk persists: Vinay Prasad has publicly criticized Pazdur and his May appointment and past actions have coincided with biotech share volatility; the Sarepta Elevidys safety episode and SRPT’s negative per‑ticker sentiment underscore how high‑profile safety cases could trigger regulatory friction. Sentiment metrics are mildly positive (0.3) with a modest market impact score (0.35), implying near‑term regulatory predictability may improve but execution and governance risks could reintroduce episodic volatility for sector names.

Key Decisions for Investors

• Increase selective exposure to oncology and rare‑disease biotechs with near‑term accelerated‑approval catalysts while keeping position sizes modest to reflect execution risk
• Monitor FDA internal signals closely—public disputes, resignations, or reversals involving Pazdur and Prasad should trigger re‑assessment and potential hedging
• Avoid adding to companies tied to ongoing safety controversies (for example Sarepta/Elevidys‑related exposure) until regulatory clarity is regained
• Watch for policy updates from CDER and HHS on conditional/accelerated approvals as potential positive catalysts for affected small‑cap biotechs